Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10751312 | 0.96 | TGFBR1 (0.33) | TGFBR1 | |
| SCHEMBL10748960 | 0.96 | TGFBR1 (0.33) | TGFBR1 | |
| SCHEMBL10754437 | 0.92 | TGFBR1 (0.33) | TGFBR1 | |
| SCHEMBL10753636 | 0.88 | TGFBR1 (0.35) | TGFBR1 | |
| SCHEMBL10753309 | 0.88 | TGFBR1 (0.37) | TGFBR1 | |
| SCHEMBL1517401 | 0.88 | TGFBR1 (0.37) | TGFBR1 | |
| SCHEMBL308679 | 0.84 | TGFBR1 (0.39) | TGFBR1 | |
| SCHEMBL514780 | 0.83 | TGFBR1 (0.38) | TGFBR1 | |
| SCHEMBL851108 | 0.79 | TSHR (0.37) | — | |
| SCHEMBL10751506 | 0.79 | TGFBR1 (0.35) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432808-B1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| US-9097839-B2 | Method for making silicone hydrogel contact lenses | NOVARTIS AG (CH) | 2015-08-04 | — | — | US | claimed |
| US-8383744-B2 | Actinically-crosslinkable siloxane-containing copolymers | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | claimed |
| US-20120172478-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2012-07-05 | — | — | US | claimed |
| US-8163206-B2 | Method for making silicone hydrogel contact lenses | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | claimed |
| EP-2432808-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | Novartis AG (CH) | 2012-03-28 | — | — | EP | claimed |
| WO-2010133680-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | NOVARTIS AG (CH) | 2010-11-25 | — | — | WO | claimed |
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | ALCON INC. (CH) | 2010-11-25 | — | — | US | claimed |
| US-20100258961-A1 | Method for making silicone hydrogel contact lenses | ALCON INC. (CH) | 2010-10-14 | — | — | US | claimed |
| US-12054590-B2 | Hydrogel polymers | GL CHEMTEC VISION INC. (CA) | 2024-08-06 | — | — | US | disclosed |
| US-20210340336-A1 | HYDROGEL POLYMERS | GL CHEMTEC VISION INC. (CA) | 2021-11-04 | — | — | US | disclosed |
| EP-3486711-A1 | LENS-FORMING MATERIALS COMPRISING PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES | Novartis AG (CH) | 2019-05-22 | — | — | EP | disclosed |
| US-10160854-B1 | Hydrogel materials | GL CHEMTEC VISION INC. (CA) | 2018-12-25 | — | — | US | disclosed |
| EP-1927882-B1 | Contact lens | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-6649722-B2 | Interpolymerization product of a (a) hydrophilic monomer with (b) a tris(siloxy)silyl group- containing monomer, (c) a wide variety of hydrophobic monomers (both aliphatic and aromatic) and usually a (d) polyfluorinated monomer | NOVARTIS AG (CH) | 2003-11-18 | — | — | US | disclosed |
| US-20020107337-A1 | Contact lens | ALCON INC. (CH) | 2002-08-08 | — | — | US | disclosed |
| EP-0675910-B1 | NOVEL MACROMONOMERS | BAUSCH & LOMB (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5563184-A | CONTACT LENSES | BAUSCH & LOMB INCORPORATED (US) | 1996-10-08 | — | — | US | disclosed |
| US-5387663-A | Polymerized with hydrophilic or hydrophobic monomers for biomedical devices, contact lenses | BAUSCH & LOMB INCORPORATED (US) | 1995-02-07 | — | — | US | disclosed |
| US-4711943-A | IMPROVED OXYGEN PERMEABILITY AND STABILITY | SOLA U.S.A. INC. (US) | 1987-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | VCL, MACF1, CFL1 | TGFBR1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.